REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. COLLABORATION AND LICENSE AGREEMENT dated byCollaboration and License Agreement • July 31st, 2020 • CureVac B.V. • Pharmaceutical preparations
This COLLABORATION AND LICENSE AGREEMENT (“Agreement”) is effective as of the 19th of December, 2019 (“Effective Date”) and is entered into by and between:
FORM OF REGISTRATION RIGHTS AGREEMENT by and among the Persons listed on Schedule A hereto, and CureVac N.V. Dated as of [●], 2020Registration Rights Agreement • July 31st, 2020 • CureVac B.V. • Pharmaceutical preparations • New York
This REGISTRATION RIGHTS AGREEMENT, dated as of [●], 2020 (as it may be amended supplemented or otherwise modified from time to time, this “Agreement”), is made among CureVac N.V., a Dutch public limited liability company (naamloze vennootschap) incorporated under the law of the Netherlands (the “Company”) and the persons listed on Schedule A hereto (each such Person, a “Holder”). Capitalized terms used in this Agreement without definition have the meaning set forth in Section 1.
DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • July 31st, 2020 • CureVac B.V. • Pharmaceutical preparations
This DEVELOPMENT AND LICENSE AGREEMENT (“Agreement”), effective as of November 9, 2017 (the “Effective Date”), is made by and between CureVac AG, a German stock corporation organized under the laws of Germany, having its principal place of business at Paul-Ehrlich-Strasse 15, 72076 Tuebingen, Germany (“CureVac”), and CRISPR Therapeutics AG, a Swiss corporation organized under the laws of Switzerland (“CRISPR”), having its principal place of business at Baarerstrasse 14, 6300 Zug, Switzerland. CureVac and CRISPR are each sometimes referred to herein as a “Party” and collectively as the “Parties.”
EXCLUSIVE COLLABORATION AND LICENSE AGREEMENT - by and between - CUREVAC GMBH - and - BOEHRINGER INGELHEIM INTERNATIONAL GMBH AUGUST 21, 2014Exclusive Collaboration and License Agreement • July 31st, 2020 • CureVac B.V. • Pharmaceutical preparations
Exhibit 4.5B Description of CureVac's License Agreements with the Ludwig Institute for Cancer Research, the University of Zurich and Geneart AG
EXECUTION COPY SIDE AGREEMENT AND AMENDMENT NUMBER ONE to the DEVELOPMENT AND OPTION AGREEMENTDevelopment and Option Agreement • July 31st, 2020 • CureVac B.V. • Pharmaceutical preparations
THIS SIDE AGREEMENT AND AMENDMENT (“Amendment Agreement”) to the DEVELOPMENT AND OPTION AGREEMENT is entered into effective as of December 1, 2016 (the “Amendment One Date”), by and between ACUITAS THERAPEUTICS INC., with offices at 2714 West 31st Avenue, Vancouver, British Columbia, V6L 2Al, Canada (“Acuitas”), and CUREVAC AG, a company incorporated in Germany whose registered office is at Paul-Ehrlich-Straf3e 15, 72076 Tübingen, Germany (“CureVac”).
CUREVAC (IDFF) Guarantee Agreement between the European Investment Bank and CureVac AGCureVac B.V. • July 31st, 2020 • Pharmaceutical preparations
Global Access Commitments AgreementCureVac B.V. • July 31st, 2020 • Pharmaceutical preparations • New York
This Global Access Commitments Agreement (including all appendices, exhibits and attachments hereto, the “Agreement”), is entered into as of February 13, 2015 (“Effective Date”), by and between the Bill & Melinda Gates Foundation, a Washington charitable trust that is a tax-exempt private foundation (the “Foundation”), and CureVac GmbH, a German limited company, together with its Affiliates (“CureVac” or the “Company”), in connection with the Foundation making a program-related investment in the Company by acquiring Series B Shares of the Company issued from the Company as part of one or more capital increases (the “Shares”) (the acquisition of Shares is referred to herein as the “Foundation Investment”). The Foundation Investment is subject to the terms and conditions of the investment documents executed in connection with the closing (“Closing”), including, without limitation, this Agreement, and the Investment and Shareholders’ Agreement (the “Shareholders’ Agreement”) among the Com
REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed.Contract • July 31st, 2020 • CureVac B.V. • Pharmaceutical preparations
The European Investment Bank having its seat at 100 blvd Konrad Adenauer,Luxembourg, L-2950 Luxembourg, represented by Tero PIETILA, Head of Division and Ayse Nil ADA, Legal Counsel
